Kim Sara S, Codi Allison, Platts-Mills James A, Pavlinac Patricia, Manji Karim, Sudfeld Chris, Duggan Christopher P, Dube Queen, Bar-Zeev Naor, Kotloff Karen, Sow Samba O, Sazawal Sunil, Singa Benson O, Walson Judd, Qamar Farah, Ahmed Tahmeed, De Costa Ayesha, Benkeser David, Rogawski McQuade Elizabeth T
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
medRxiv. 2024 Oct 28:2024.10.27.24316217. doi: 10.1101/2024.10.27.24316217.
We used machine learning to identify novel strategies to target azithromycin to the children with watery diarrhea who are most likely to benefit.
Using data from a randomized trial of azithromycin for watery diarrhea, we developed personalized treatment rules given sets of diagnostic, child, and clinical characteristics, employing a robust ensemble machine learning-based procedure. For each rule, we estimated the proportion treated under the rule and the average benefits of treatment.
Among 6,692 children, treatment was recommended on average for approximately one third of children. The risk of diarrhea on day 3 was 10.1% lower (95% CI: 5.4, 14.9) with azithromycin compared to placebo among children recommended for treatment. For day 90 re-hospitalization and death, risk was 2.4% lower (95% CI: 0.6, 4.1) with azithromycin compared to placebo among those recommended for treatment. While pathogen diagnostics were strong determinants of azithromycin effects on diarrhea duration, host characteristics were more relevant for predicting benefits for re-hospitalization or death.
The ability of host characteristics to predict which children benefit from azithromycin with respect to the most severe outcomes suggests appropriate targeting of antibiotic treatment among children with watery diarrhea may be possible without access to pathogen diagnostics.
我们运用机器学习来确定新策略,以便将阿奇霉素用于最可能从中受益的水样腹泻儿童。
利用阿奇霉素治疗水样腹泻的一项随机试验的数据,我们根据一系列诊断、儿童及临床特征,采用一种基于稳健集成机器学习的程序制定个性化治疗规则。对于每条规则,我们估计了按照该规则接受治疗的比例以及治疗的平均益处。
在6692名儿童中,平均约三分之一的儿童被建议接受治疗。在被建议接受治疗的儿童中,与安慰剂相比,阿奇霉素治疗组第3天腹泻风险降低10.1%(95%置信区间:5.4,14.9)。对于第90天再次住院和死亡情况,与安慰剂相比,阿奇霉素治疗组风险降低2.4%(95%置信区间:0.6,4.1)。虽然病原体诊断是阿奇霉素对腹泻持续时间影响的重要决定因素,但宿主特征对于预测再次住院或死亡的益处更为相关。
宿主特征能够预测哪些儿童在最严重结局方面从阿奇霉素中受益,这表明在无法进行病原体诊断的情况下,对水样腹泻儿童进行抗生素治疗的合理靶向给药或许是可行的。